Australia markets open in 9 hours 39 minutes

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
9.71-0.11 (-1.12%)
At close: 04:00PM EST
9.70 -0.01 (-0.10%)
After hours: 06:46PM EST

Teva Pharmaceutical Industries Limited

124 Dvora Hanevi’a Street
Tel Aviv 6944020
972 3 914 8213

IndustryDrug Manufacturers - Specialty & Generic
Full-time employees34,004

Key executives

NameTitlePayExercisedYear born
Mr. Eliyahu Sharon KalifExecutive VP & CFO2.01MN/A1973
Mr. Eric DrapeExecutive Vice President of Global Operations1.91MN/A1962
Mr. Mark SabagExecutive Vice President of International Markets Commercial1.92MN/A1971
Mr. Richard D. FrancisPresident, CEO & DirectorN/AN/A1968
Mr. Amir WeissSenior VP & Chief Accounting OfficerN/AN/A1977
Ran MeirHead of Investor RelationsN/AN/AN/A
Mr. David M. StarkExecutive VP & Chief Legal OfficerN/AN/A1969
Kathleen VeitSenior Vice President, Global Compliance & Ethics OfficerN/AN/AN/A
Ms. Vikki ConwayActing Head of Global Human ResourcesN/AN/AN/A
Mr. Kevin C. MannixSenior Vice President of Investor RelationsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration with MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia, as well as a collaboration with Sanofi to co-develop and co-commercialize TEV-48574 asset, a novel anti-TL1A therapy for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Corporate governance

Teva Pharmaceutical Industries Limited’s ISS governance QualityScore as of 1 December 2023 is 5. The pillar scores are Audit: 9; Board: 3; Shareholder rights: 5; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.